Please Note: Blog posts are not selected, edited or screened by Seeking Alpha editors.

Oxygen Biotherapeutics, Inc. (NASDAQ: OXBT) $59M (MarketCap) Expands Dermacyte Skin Care Products Sales Territory

|Includes: Tenax Therapeutics, Inc. (TENX)
As we grow older, the circulation of oxygen in our body starts to decrease and the body’s ability to deliver oxygen to dermal tissue deteriorates. Lower oxygen levels affect the body’s ability to make collagen, which provides structural support to the skin. As collagen production declines, fine lines and wrinkles become more noticeable. The lack of oxygen can also cause skin to age prematurely, increasing the appearance of fine lines and age spots, making skin look dull and dry. In other words, oxygen is essential in maintaining radiant, young looking skin.

To provide a solution to this issue, Oxygen Biotherapeutics, Inc. (NASDAQ: OXBT) is developing medical and cosmetic products that efficiently deliver oxygen to tissues in the body. Their experiments resulted in the discovery of Oxycyte Technology, a unique and highly effective carrier that delivers oxygen to damaged tissues. This technology allows the transfer of large amounts of dissolved natural oxygen without the use of chemical activators like hydrogen peroxide, which is known to dry and bleach skin. It inspired the creation of a new oxygen-enriched skincare product, known as Dermacyte Oxygen Concentrate. Potential benefits from increased oxygenation to the skin include a decrease in the appearance of fine lines, wrinkles, and dryness. The company plans to introduce a formulation for the area around the eye this summer.

Today, the company is trading at 2.80, up .3628 or 14.87% after its announcement of the expansion of its sales territory for Dermacyte into 2 additional states, Arizona and Michigan. With a combined population of more than 2.5 million and a median age of just over 30, these 2 cities host over 750 spas and salons and more than 300 dermatologists. This is a very promising market for the company, and they plan to sell Dermacyte products to medical practitioners, salons, and beauty and health spas in Detroit, Phoenix, and their surrounding communities.

"The roll out of Dermacyte is progressing with the addition of these two markets," said Chairman and CEO Chris Stern. "Our strategy is to market it as a high-level cosmetic in various specific formulations. Currently we are developing an internal sale team for certain markets, such as New York, Los Angeles, and Miami supplemented by contract sales representatives in other parts of the country. We plan to gradually add territory sales agreements to cover the U.S. and Canada."

To view this article at World Market Media click on the link below:


Disclosure: no positions